Express Pharma
Home  »  Latest Updates  »  DRL launches Paricalcitol injection in the US market

DRL launches Paricalcitol injection in the US market

12

It is the first ANDA product launched in the US market

Dr. Reddy’s Laboratories (DRL) recently  launched Paricalcitol injection, USP, in 2 mcg, 5 mcg, 10 mcg. It is a therapeutic equivalent generic version of Zemplar  (paricalcitol) Injection in the US market approved by the US Food & Drug Administration. It is the first ANDA product launched in the US market.

The Zemplar brand and generic had US sales of approximately $ 22.5 million MAT for the recent twelve months ending in July 2016 according to IMS Health.

EP News Bureau

Comments are closed.